European Psychiatry
June 1, 2026
T. Sagues, A. Barnes, C. Fernández et al.
Introduction Intranasal esketamine has emerged as an innovative option for the management of treatment-resistant depression (TRD), offering a novel mechanism of action and rapid antidepressant effects. However, evidence regarding the clinical trajectory after treatment discontinuation remains limited, raising questions about the durability of its therapeutic benefits and the optimal maintenance...
Journal of Psychopharmacology
April 2018
Verònica Gálvez, Adrienne Li, Christina Huggins et al.
Ketamine research in depression has mostly used intravenous, weight-based approaches, which are difficult to translate clinically. Intranasal (IN) ketamine is a promising alternative but no controlled data has been published on the feasibility, safety and potential efficacy of repeated IN ketamine treatments. This randomised, double-blind, placebo-controlled pilot study compared a 4-week course...
The Lancet Psychiatry
2018
Brooke L Short, J. Fong, Verònica Gálvez et al.
551 citations
This is the first systematic review of the safety of ketamine in the treatment of depression after single and repeated doses. We searched MEDLINE, PubMed, PsycINFO, and Cochrane Databases and identified 288 articles, 60 of which met the inclusion criteria. After acute dosing, psychiatric, psychotomimetic, cardiovascular, neurological, and other side-effects were more frequently reported after...
American Journal of Geriatric Psychiatry
November 2017
Duncan George, Verònica Gálvez, Donel Martin et al.
To assess the efficacy and safety of subcutaneous ketamine for geriatric treatment-resistant depression. Secondary aims were to examine if repeated treatments were safe and more effective in inducing or prolonging remission than a single treatment. In this double-blind, controlled, multiple-crossover study with a 6-month follow-up (randomized controlled trial [RCT] phase), 16 participants (≥60...
Comprehensive Psychiatry
February 2017
Verònica Gálvez, Stevan Nikolin, Kerrie-Anne Ho et al.
Animal studies suggest that neural plasticity may play a role in the antidepressant effects of a single ketamine dose. However, the potential effects of repeated ketamine treatments on human neuroplasticity are unknown. This pilot RCT study measured plasticity-induced changes before and after a ketamine course, in three treatment-resistant depressed subjects, who were randomized to receive 8...
Acta Psychiatrica Scandinavica
July 1, 2016
C. Loo, Verònica Gálvez, E. O'Keefe et al.
This pilot study assessed the feasibility, efficacy and safety of an individual dose‐titration approach, and of the intravenous (IV), intramuscular (IM) and subcutaneous (SC) routes for treating depression with ketamine.